In CRC, mutations in the Kras oncogene and those of the Apc gene lead to greater cell proliferation, the MAPK signaling caused by mutated KRAS presents ERK hyperphosphorylation, which activates different effector mechanisms such as the G1/S phase transition, and the inhibition of apoptosis. This evidence concerns the gene KRAS and colorectal carcinoma.